VGX Pharmaceuticals to present at the 11th Annual Conference on Vaccine Research

Blue Bell, PA – May 5, 2008 –

VGX Pharmaceuticals Inc. (VGX) announced today that the Company will make multiple presentations regarding its SynCon™ pandemic flu DNA vaccine (VGX-3400) and CELLECTRA® DNA Delivery device at the 11th Annual Conference on Vaccine Research. The Conference is sponsored by the National Foundation for Infectious Diseases (NFID) and will take place May 5-7, 2008 at Baltimore's Marriott Waterfront Hotel.

Dr. Ruxandra Draghia-Akli, VGX's Vice President of Research, will deliver an oral presentation entitled "Improved immune responses following intradermal (ID) vaccination of a consensus influenza DNA vaccine using electroporation (EP) in non-human primates." This presentation highlights VGX's comprehensive development of novel methodologies for a universal influenza DNA vaccine using the Company's CELLECTRA® constant current electroporation device. The presentation reports on the novel ID delivery of VGX-3400 in rhesus monkeys, which generated significant antibody-based and T cell-based immune responses. VGX-3400 is the Company's rationally constructed SynCon™ pandemic flu DNA vaccine. These findings demonstrate that the delivery of influenza antigens using ID+EP could be an important vaccination strategy and could have advantages over current influenza vaccine approaches.

A second poster presentation will present study data showing that ferrets vaccinated with VGX-3400 were fully protected from illness and subsequent death in a challenge using an unmatched Vietnamese strain of avian flu virus. During the experiments, 100% of the ferrets treated with VGX-3400 survived, while 100% of the control animals died. Ferrets represent the most relevant pre-clinical influenza animal model for humans, and data from previous challenges demonstrate that VGX-3400 also protects mice from the unmatched Vietnamese strain of avian flu virus. All vaccines used were delivered with VGX's patented CELLECTRA® DNA delivery device. The results of both animal challenges should strongly support an Investigative New Drug (IND) application for VGX-3400, which the Company expects to file by June 2008.

VGX Pharmaceuticals' SynCon™ DNA vaccine antigens are designed by aligning numerous primary sequences and choosing the most common amino acid or base pair at each site by using proprietary bioinformatics approaches. The SynCon™ DNA vaccines in combination with the CELLECTRA® delivery device provide greater levels of cross-reactive immune responses than those produced by more traditional vaccines.

Cautionary Factors That May Affect Future Results - Materials in this Web site contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the

outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, PENNVAX™-B for HIV infection, which is in 2 separate Phase I clinical trials, and VGX-1027 for inflammatory diseases, which is in Phase I clinical trials. In addition, The Company has filed an IND for VGX-3200, a novel DNA therapy that utilizes GHRH for the treatment of cancer cachexia and anemia. VGX has established a vertically-integrated DNA Vaccines and Therapies Platform with extensive capabilities including SynCon™ DNA-based product candidates, the patented CELLECTRA® delivery device, and efficient cGMP plasmid manufacturing facilities. The cGMP facilities are used for VGX's own product supplies and for contract manufacturing. Vertical control over key aspects of product development has enabled the Company to consistently develop multiple product candidates, from bench-to-IND filing, within 1 year. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas
Senior Vice-President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com